Clinical Trial Budgeting Faces Pressure To Modernize

By Katie Rothstein, Director, Data Delivery, Suvoda

Clinical trial budgeting remains one of the most persistent sources of delay in study startup. Investigator grant negotiations are often built on outdated or inconsistent cost data, leading to misaligned expectations between sponsors and sites, disconnected manual workflows, and a lack of clear ways to measure progress. These inefficiencies carry real costs: delayed Phase II/III trials can lose roughly $40,000 per day, and nearly a quarter of sites report declining trials outright due to budget disagreements.

Real-time fair market value (FMV) benchmarking offers a path forward. By grounding budget proposals in current, real-world site cost data across geographies, therapeutic areas, and study phases, sponsors and sites can move past guesswork and toward faster, more transparent negotiations. For organizations facing recurring startup delays, the underlying issue is often not effort, but the data foundation negotiations are built upon. Reassessing how budgets are benchmarked is a practical step toward shortening negotiation cycles and building a more collaborative, sustainable clinical research process.